Phase 1 study to evaluate Siglec-6-targeted CAR-T therapy in relapsed or refractory AML and CLL patients, marking a major milestone for T-CURX’s scalable non-viral CAR-T platform
The addition of the Halcyon system represents a significant milestone in the hospital’s oncology services
Proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovative in vivo CAR-T assets into clinical trials one year earlier
India already has talent, digital infrastructure, entrepreneurial energy, clinical expertise, and policy momentum. The next phase demands coordinated execution and building institutions that can hold the ecosystem together over time
The device is designed for early and accurate diagnosis of obstructive airway diseases such as COPD, and Asthma
New pediatric nebulizer combines playful design and engaging features to make breathing treatments less stressful for children and parents
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Collaboration integrates AJICAP™ technology with global manufacturing capabilities to streamline antibody-drug conjugate pipelines
ANDA approval for 100 mg and 150 mg capsules targeting idiopathic pulmonary fibrosis opens access to a $3.76 billion market in USA
Subscribe To Our Newsletter & Stay Updated
